XRP Primed for 2017-Style Explosion as Bullish Formations Return
XRP flashes unmistakable signals of another historic surge as technical patterns mirror the legendary 2017 bull run.
Market Déjà Vu: History Rhymes
Chart formations that preceded XRP's epic 2017 ascent are reappearing with uncanny similarity. The same bullish indicators that sparked that 20,000% rocket ride now suggest another massive move could be brewing.
Technical Alignment: Perfect Storm
Key resistance levels shattered while volume patterns echo the explosive pre-bull market conditions from eight years ago. Trading activity suggests institutional money positioning for what could become another generational opportunity.
Market Psychology: Fear Turns Greedy
The same emotional triggers that fueled the last parabolic move—FOMO, breakout confirmation, and network effect anticipation—are regenerating across trading communities. Even traditional finance analysts who once dismissed crypto now scramble to understand the charts.
Regulatory Tailwinds: Clear Skies Ahead
Recent legal clarity provides the fundamental backing that technical analysis alone couldn't deliver. The combination creates what traders call a 'perfect setup'—where fundamentals and technicals align for maximum momentum.
Remember when your broker told you crypto was a fad back in 2017? The charts are whispering that they might be wrong again—only louder this time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
VB4-P5 is a candidate in development for the treatment of rare and prevalent forms of kidney disease. XORTX Therapeutics noted that chronic kidney disease affects 14% of adults globally. That includes 35 million to 37 million in the U.S. Early data from investigations of VB4-P5 show it has the potential to inhibit and possibly reverse kidney fibrosis.
XORTX Therapeutics CEO Dr. Allen Davidoff said, “The opportunity to acquire the VB4-P5 program was highly compelling. This program is underpinned by a novel, patented small molecule with robust global patent protection and strong preclinical evidence. It is directly aligned with our strategic focus on developing innovative therapies for progressive kidney disease, and it builds upon our mission to bring new classes of treatments to patients suffering from rare renal disorders.”
XORTX Therapeutics Stock Movement Today
XORTX Therapeutics stock was up 21.18% on Friday but remained down 24.71% year-to-date. The shares have also decreased 54.79% over the past 12 months.
Today’s news excited investors and triggered heavy trading of XRTX stock. This had some 7 million shares traded as of this writing, compared to a three-month daily average of about 44,000 units.
It’s unclear the effect this news will have on Vectus Biosystems Limited stock, as the Australian Securities Exchange is currently closed. Investors will have to wait until Monday to see what this deal means for VBS shares.
